Transthyretin Amyloidosis (ATTR) drugs
Showing the single result
Transthyretin Amyloidosis (ATTR) | Landscape & Forecast | Competitive Landscape & Forecast, 2020-2030$5,250.00 – $15,750.00
The Transthyretin Amyloidosis (ATTR) report provides the detailed overview of the disease and exhaustive understanding of historical and forecasted epidemiology. It highlights the prevailing treatment patterns, potential upcoming drugs and also identifies better of the market opportunities by providing the historical and forecasted market revenue, sales trends, and drug uptake during the study period from 2019-2030.